New York, New York, USA, November 18, 2026
Breakthrough T1D, the Lupus Research Alliance and the National Multiple Sclerosis Society have jointly announced nearly $1 million in research funding to advance the understanding of autoimmune diseases and identify potential new therapeutic approaches. The funding is being awarded through the organisations’ Common Mechanisms in Autoimmunity Insight Award, a collaborative research programme investigating biological mechanisms shared across type 1 diabetes (T1D), systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Six researchers from leading academic institutions in the United States and Europe have been selected to receive funding of up to $150,000 each for one-year pilot investigations. The programme aims to uncover common immune-system pathways, identify disease-specific differences and accelerate discoveries that could support the development of treatments for multiple autoimmune conditions.
Nearly $1 Million Supports Six Autoimmune Research Projects
The latest funding round represents another step in the organisations’ efforts to encourage collaboration across traditionally separate autoimmune research fields. Autoimmune diseases develop when the immune system mistakenly attacks the body’s own cells, tissues or organs, potentially causing inflammation, tissue damage and loss of function. Although conditions such as T1D, lupus and MS affect different organs, they may share underlying genetic, environmental and immunological mechanisms. The programme seeks to understand these connections and reduce duplication in research efforts. Six investigators have been selected through a rigorous review process, with each receiving up to $150,000 to conduct a one-year pilot study. The projects will examine genetic risk interactions, immune-cell behaviour, environmental exposures, inflammatory signalling pathways and opportunities to repurpose existing medicines. By supporting research across different scientific disciplines, the initiative aims to generate findings that could inform future therapeutic development and improve understanding of why autoimmune diseases develop and progress.
Research Targets Shared Immune Pathways and Disease Risks
The selected projects cover several important areas of autoimmune research. Maya Arce, PhD, of the Arc Institute will investigate how combinations of genetic risk variants disrupt immune signalling pathways, particularly those regulating CD4-positive T cells. Ka Lung Cheung, PhD, of the Icahn School of Medicine at Mount Sinai will study the Th17 immune pathway and the role of its regulator, Hdac7, in inflammatory activity across models of MS, SLE and T1D. Gabriela Fragiadakis, PhD, from the University of California, San Francisco, will analyse large-scale single-cell datasets containing more than one million immune cells to identify shared patterns of cellular behaviour and gene activity across autoimmune conditions. At the University of Colorado, Jill Norris, PhD, MPH, will investigate whether environmental chemicals, including PFAS, phenols and phthalates, are associated with the development and progression of autoimmune diseases. Her research will examine samples from individuals at risk before diagnosis to explore potential environmental contributors.
Drug Repurposing and Precision Medicine Drive Future Opportunities
The remaining projects will explore how existing scientific knowledge and advanced analytical methods could support future treatment strategies. Thomas Pieber, MD, of the Medical University of Graz in Austria, will investigate the JAK/STAT signalling pathway by studying how approved JAK inhibitors affect immune cells from people with T1D, lupus and MS. The objective is to identify shared and disease-specific treatment responses and assess opportunities to repurpose existing medicines. Ingrid Kockum, PhD, of Karolinska Institutet in Sweden, will combine genetic information, health registry records and lifestyle data with advanced analytical and artificial intelligence tools. Her project aims to identify common and distinct disease mechanisms, improve early prediction models and uncover opportunities for more personalised prevention and treatment strategies. Together, these investigations address important questions about immune-system regulation, genetic susceptibility and the biological differences that influence how patients respond to treatment. Since its launch in 2021, the Common Mechanisms in Autoimmunity programme has supported 19 pilot investigations, reflecting the organisations’ continued commitment to collaborative scientific discovery. Earlier research supported through the initiative also contributed to a study by Aly Khan, PhD, at the University of Chicago, which identified small protein fragments called peptides that may trigger autoimmune diseases. The work was published in Nature Biotechnology and highlighted the potential of understanding immune-system triggers to support more personalised treatment development.
The latest award announcement reinforces the importance of funding early-stage research that investigates biological mechanisms across multiple diseases rather than studying each condition in isolation. The 2027 Common Mechanisms in Autoimmunity Insight Award application round is now open, with applications due January 7, 2027. Although the newly funded projects are exploratory investigations rather than clinical trials, their findings could help identify future drug targets, improve disease prediction and guide the development of therapies for people living with autoimmune conditions. The collaboration demonstrates how coordinated research funding can help accelerate scientific discovery across type 1 diabetes, lupus and multiple sclerosis.
Source: Breakthrough T1D, Lupus Research Alliance press release



